Comparison of clinical outcomes and risk factors for Covid-19 infection in cancer patients without anticancer treatment and noncancer patients

Background Previous studies have shown that cancer patients have higher rates of coronavirus disease 2019 (COVID-19) infection and mortality than noncancer patients. However, the differences between cancer patients undergoing regular follow-up without anticancer treatment and noncancer patients with COVID-19 have remained insufficiently investigated. Methods A retrospective case–control study of 52 patients with COVID-19 infection was performed with a 1:3 matched proportion of cancer patients undergoing regular follow-up without anticancer treatment and noncancer patients. The demographic characteristics, clinical data, laboratory tests, treatment, and complications of patients were collected from medical records. Chi-square tests and univariate and multivariate regressions were performed to assess the differences between these two cohorts of COVID-19 patients with and without cancer and risk factors for severe events in COVID-19 patients. Results Increased C-reactive protein (CRP) (>4 mg/L) ( p = 0.015) and lactate dehydrogenase (LDH) (>243 IU/L) ( p = 0.038) were identified as risk factors for severe events in all enrolled COVID-19 patients based on multivariate analysis, but cancer as a chronic disease ( p = 1.000) was not identified as an independent risk factor for severe events in COVID-19 patients. Compared with noncancer patients, cancer patients had a significantly longer median hospitalization time (29 days vs. 19 days, p = 0.048) and a higher incidence of hypoalbuminemia complications (84.6 vs. 46.2%, p = 0.016). Conclusions Increased CRP and LDH were risk factors for severe events in all enrolled COVID-19 patients, and an increased incidence of hypoalbuminemia complications and longer hospitalization were noted in COVID-19 cancer patients undergoing regular follow-up without anticancer treatment compared with noncancer patients

2019-20 coronavirus outbreak · Bioinformatics · Biology · Cancer · Disease · Intensive care medicine · Outbreak · COVID-19 and healthcare impacts · COVID-19 Clinical Research Studies · Medicine · Vitamin C and Antioxidants Research · Internal Medicine · Oncology · Virology

• Cancer patients in Sars-CoV-2 infection

  Open Access•Wenhua Liang, Wei‐jie Guan et al.•The Lancet Oncology•2020

  Incluir item

• Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

  Open Access•Victor M Corman, Olfert Landt et al.•Eurosurveillance•2020

  Incluir item

• The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

  Mervyn Singer, Clifford S Deutschman et al.•JAMA•2016

  Incluir item

• Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

  Chaomin Wu, Xiaoyan Chen et al.•JAMA Internal Medicine•2020

  Incluir item

• Omicron Sars-CoV-2 variant

  Open Access•Salim S Abdool Karim, Quarraisha Abdool Karim•The Lancet•2021

  Incluir item

• Clinical Characteristics of Coronavirus Disease 2019 in China

  Wei‐jie Guan, G Giovanny Cárdenas et al.•New England Journal of Medicine•2020

  Incluir item

• Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

  Open Access•Qun Li, Xuhua Guan et al.•New England Journal of Medicine•2020

  Incluir item

• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

  Open Access•Chaolin Huang, Yeming Wang et al.•The Lancet•2020

  Incluir item

• Epidemiological, Radiographical, and Laboratorial Characteristics of Chinese Asymptomatic Cases With Covid-19

  Open Access•Haohao Yan, Yudan Ding et al.•Frontiers in Public Health•2022

  Incluir item